annb0t
Top 20
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for TLX66 (90Y-besilesomab), for conditioning treatment prior to hematopoietic stem cell transplant (HSCT). The granting of an ODD for TLX66 qualifies Telix for various drug development incentives, which may include FDA administered market exclusivity f...
>>> Read more: Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
>>> Read more: Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
